Analyst Ratings For Alder Biopharmaceuticals Inc (NASDAQ:ALDR)
Today, Stifel Nicolaus initiated coverage on Alder Biopharmaceuticals Inc (NASDAQ:ALDR) with a Buy with a price target of $30.00.
There are 9 Buy Ratings, 2 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Alder Biopharmaceuticals Inc (NASDAQ:ALDR) is Buy with a consensus target price of $22.40 per share, a potential 16.67% upside.
Some recent analyst ratings include
- 8/7/2018-Stifel Nicolaus initiated coverage with a Buy rating.
- 8/6/2018-Piper Jaffray Companies initiated coverage with a Overweight rating.
- 6/27/2018-Needham & Company LLC initiated coverage with a Buy rating.
- 6/13/2018-Canaccord Genuity Reiterated Rating of Buy.
- 6/7/2018-Mizuho Reiterated Rating of Buy.
- 4/24/2018-Goldman Sachs Group initiated coverage with a Neutral rating.
- On 8/1/2018 Jeffrey T L Smith, Director, sold 5,040 with an average share price of $19.54 per share and the total transaction amounting to $98,481.60.
- On 8/1/2018 John A Latham, Insider, sold 24,999 with an average share price of $19.55 per share and the total transaction amounting to $488,730.45.
- On 7/2/2018 Jeffrey T L Smith, Director, sold 12,161 with an average share price of $15.49 per share and the total transaction amounting to $188,373.89.
- On 7/2/2018 John A Latham, Insider, sold 24,999 with an average share price of $15.48 per share and the total transaction amounting to $386,984.52.
- On 6/1/2018 Jeffrey T L Smith, Director, sold 12,161 with an average share price of $17.85 per share and the total transaction amounting to $217,073.85.
- On 6/1/2018 Mark James Litton, Insider, sold 22,727 with an average share price of $17.84 per share and the total transaction amounting to $405,449.68.
- On 5/16/2018 Jeffrey T L Smith, Insider, sold 12,161 with an average share price of $15.03 per share and the total transaction amounting to $182,779.83.
About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)
Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland. The company's lead pivotal-stage product candidate, Eptinezumab, a monoclonal antibody inhibiting calcitonin gene-related peptide, which is in Phase III pivotal trials for the prevention of migraine. Its product candidate pipeline also includes ALD1910, a preclinical monoclonal antibody that targets pituitary adenylate cyclase-activating polypeptide-38; and Clazakizumab, that has completed two Phase 2b clinical trials designed to block the pro-inflammatory cytokine IL-6. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.
Recent Trading Activity for Alder Biopharmaceuticals Inc (NASDAQ:ALDR)
Shares of Alder Biopharmaceuticals Inc closed the previous trading session at 19,20 +0,20 1,05 % with 19.95 shares trading hands.